Tekla Life Sciences Investors
NYSE: HQL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange
- Sector
- Financial Services
- Industry
- Asset Management
- CEO
- Daniel R. Omstead
- Headquarters
- Philadelphia, United States
- IPO year
- 1992
- Market cap
- $574.4M
- Website
- https://www.teklacap.com/hql.html
Loading HQL…
Loading profile data…Frequently asked questions about HQL
What does Tekla Life Sciences Investors (HQL) do?
Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies with...
Where does HQL trade?
Tekla Life Sciences Investors (HQL) trades on the New York Stock Exchange.
What sector is HQL in?
Tekla Life Sciences Investors (HQL) operates in the Financial Services sector, specifically in the Asset Management industry.
Who is the CEO of Tekla Life Sciences Investors?
Daniel R. Omstead is the chief executive officer of Tekla Life Sciences Investors (HQL).
Where is Tekla Life Sciences Investors headquartered?
Tekla Life Sciences Investors is headquartered in United States.
Does HQL pay a dividend?
Yes — Tekla Life Sciences Investors (HQL) paid a trailing twelve-month dividend of USD 2.04 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did HQL go public?
Tekla Life Sciences Investors (HQL) completed its initial public offering in 1992.